Tag:
Prevnar
Latest Headlines
Latest Headlines
Pfizer points to pandemic potential of Prevnar 13
In pandemic flu preparation, a lot of focus is placed on protecting against the specific viral strain. Yet analysis of the 1918 pandemic shows secondary bacterial pneumonia directly caused many of the deaths. This brings Pfizer's Prevnar 13 into play, and the Big Pharma is talking up its role.
Pfizer sales drop 16%, falling short of expectations
Once again, Lipitor's patent loss gave Pfizer's ($PFE) quarterly results a big wallop. The cholesterol fighter's sales plummeted by 71% year over year, to $749 million. That drop, if a bit bigger than anticipated, was expected; it's been expected for years. So, the company's 16% drop in sales, to about $14 billion, is no wake-up call.
20 Top-selling Vaccines -- H1 2012
As H1 came to a close, FierceVaccines decided to take a look at which prophylactic vaccines flew off the shelves--and which companies made the sales.
The 20 top-selling vaccines in H1 2012
As H1 came to a close, FierceVaccines decided to take a look at which prophylactic vaccines flew off the shelves--and which companies made the sales. Take a look at the full list >>
Pfizer nears animal health IPO as cost-cutting boosts profits
Pfizer posted higher profits for the second quarter. That's the good news. The not-so-good is that sales dropped by 9%, thanks to increased competition for the newly off-patent Lipitor. The increase in profits came on the back of cost cuts across the company, including big reductions in R&D.
UPDATED: In U.K., Pneumovax trumps Pfizer's Prevnar 13
Looks like Pfizer's pneumococcal vaccine Prevenar 13 is down on its luck in the U.K.; the Joint Committee on Vaccination and Immunisation shafted the shot in favor of Pneumovax for adults and high-risk individuals.
Pfizer targets miniblockbuster prospects as Lipitor patent expires
Pfizer ( $PFE ) has been gearing up for the expiration of Lipitor's patent for years, and with the big day finally upon us, analysts and industry watchers are weighing in on the R&D course that the
FDA panel favors Pfizer's Prevnar 13 for expanded use
An FDA advisory panel backed Pfizer's ( $PFE ) Prevnar 13 vaccine for use in adults age 50 and older to stave off pneumonia, meningitis, and other pneumococcal infections. The committee voted 14-1 in
FDA staffers back Pfizer's Prevnar vax for adults
Will Pfizer ( $PFE ) succeed at broadening use of its star vaccine? A report from FDA reviewers suggest it might. In a pre-advisory committee review, agency staffers said the Prevnar 13 vaccine was
To pump up Prevenar, Pfizer looks to rural China
Like any country, China isn't one market, but many. Strategies for capturing share and growing sales in cities won't necessarily work in rural areas. And to grow as much as drugmakers want to in
